Experimental as well as computational HT-techniques are already commonly used to screen for potential drug candidates and can help identify potent inhibitors to treat diseases such as malaria or PVB19 infections. Experimental workflows utilizing high-throughput concepts are becoming more sophisticated, thriving from simple viability-based readouts to allow more complex insights into biological systems and the fundamental dogma of biology while maintaining the advantages that came along with HT screening. Miniaturization is not just a logical consequence of the economical consideration that experiments on a macroscopic scale consume more time and materials compared to a microscopical approach, but also a consequence of our own responsibility as researchers to minimize resource consumption as much as possible to allow sustainable scientific progression. Thus, miniaturization techniques need to develop further, away from the purely pharmacological or biological application, to fit the need of all research areas, especially the chemistry and material science related ones, to allow resource conserving ways of driving science forward.